Quick Answer
PUMA BIOTECHNOLOGY, INC. reported R&D Expense of $71.87 million for fiscal year 2021.
PUMA BIOTECHNOLOGY, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2021 | $71.87M | -26.4% |
| 2020 | $97.65M | -26.5% |
| 2019 | $132.85M | -19.4% |
| 2018 | $164.85M | -20.7% |
| 2017 | $207.81M | -6.7% |
| 2016 | $222.80M | +6.9% |
| 2015 | $208.47M | +69.6% |
| 2014 | $122.92M | +172.9% |
| 2013 | $45.05M | -9.2% |
| 2012 | $49.64M | +5909.2% |
| 2011 | $826.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2022 | $11.97M | -35.8% | -21.5% |
| March 31, 2022 | $15.24M | -24.7% | -19.1% |
| September 30, 2021 | $18.84M | -19.3% | +1.1% |
| June 30, 2021 | $18.64M | -24.5% | -7.9% |
| March 31, 2021 | $20.23M | -20.5% | -13.3% |
| September 30, 2020 | $23.34M | -22.3% | -5.5% |
| June 30, 2020 | $24.69M | -33.0% | -3.0% |
| March 31, 2020 | $25.45M | -28.8% | -15.2% |
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -26.4% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2021 period, PUMA BIOTECHNOLOGY, INC.’s r&d expense has grown by 8601.0% (from $826.0 thousand to $71.87 million).
- The most recent figure is from PUMA BIOTECHNOLOGY, INC.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 3, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: